Skip to main content

Overcoming the boundaries of gene editing by unlocking the full potential of recombinases.

Accessing a seamless approach to treating severe disease

About Us

Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Our technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes. We are applying this novel technology to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.

Leadership

The Seamless Therapeutics leadership team is comprised of passionate industry leaders with decades of proven expertise. They share a common vision to transform the gene-editing landscape.

Albert Seymour, PhD
President & CEO
Managing Director, GmbH

Deborah Kinch, PhD
Chief Development Officer

Felix Lansing, PhD
Scientific Co-Founder & CTO

Anne-Kristin Heninger, PhD
Co-Founder & Head of Operations Dresden
Managing Director, GmbH

Board of Directors & Advisors

Adam Rosenberg
Chairman

Dmitrij Hristodorov, PhD
Board Director

Regina Hodits, PhD
Board Director

Investors

Seamless Therapeutics is supported by leading life-science investors.

Careers

We are a dynamic team pioneering a groundbreaking new gene-editing approach with a deep understanding of recombinases and their potential in repairing genes that cause serious diseases. We foster creativity, leadership, and teamwork, and empower our people to make decisions and contribute positively to our goals. We also offer a supportive environment for colleagues to learn from each other, tackle challenges together, and celebrate our achievements.

GO TO CAREER PAGE

Seamless Therapeutics, Inc.
10 Maguire Rd
Building 2 Suite 100
Lexington, MA 02421
USA

T: 508 310 6880

Seamless Therapeutics GmbH
Tatzberg 47/49
01307 Dresden
Germany

T: +49 351 212 469 00
E: info@seamlesstx.com